BTIG Downgrades Zimmer Biomet to Neutral, Citing Limited Upside Amid Growth Challenges

lunes, 23 de marzo de 2026, 12:18 pm ET1 min de lectura
ZBH--

BTIG downgraded Zimmer Biomet to Neutral from Buy due to weak growth momentum and limited catalysts. The brokerage cited slowing organic revenue growth, limited support from new products, and operational changes. Zimmer Biomet's stock trades at 10.5x forward earnings, below peers, and BTIG expects limited share performance despite ongoing efforts to improve growth and profitability.

BTIG Downgrades Zimmer Biomet to Neutral, Citing Limited Upside Amid Growth Challenges

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios